Risk factors and cardio-metabolic outcomes associated with metabolic-associated fatty liver disease in childhood.
Cardio-metabolic health
Liver fat
Metabolic-associated fatty liver disease
Pediatric liver fat
Pediatric metabolic health
Pediatric obesity
Journal
EClinicalMedicine
ISSN: 2589-5370
Titre abrégé: EClinicalMedicine
Pays: England
ID NLM: 101733727
Informations de publication
Date de publication:
Nov 2023
Nov 2023
Historique:
received:
05
06
2023
revised:
13
09
2023
accepted:
14
09
2023
medline:
19
10
2023
pubmed:
19
10
2023
entrez:
19
10
2023
Statut:
epublish
Résumé
Non-Alcoholic Fatty Liver Disease (NAFLD) is defined as increased liver fat percentage, and is the most common chronic liver disease in children. Rather than NAFLD, Metabolic-Associated Fatty Liver Disease (MAFLD), defined as increased liver fat with presence of adverse cardio-metabolic measures, might have more clinical relevance in children. We assessed the prevalence, risk-factors and cardio-metabolic outcomes of MAFLD at school-age. This cross-sectional analysis was embedded in an ongoing population-based prospective cohort study started in 2001, in the Netherlands. In 1910 children of 10 years, we measured liver fat fraction by magnetic resonance imaging (MRI), body mass index (BMI), blood pressure, and lipids, insulin, and glucose concentrations. Childhood lifestyle factors were obtained through questionnaires. MAFLD was defined as ≥2% liver fat in addition to excess adiposity (BMI or visceral adiposity), presence of metabolic risk (blood pressure, triglycerides and HDL-concentrations) or prediabetes (glucose). Of all children, 49.6% had ≥2% liver fat, and 25.2% fulfilled the criteria of MAFLD. Only non-European descent was associated with increased odds of MAFLD at nominal significance (Odds Ratio 1.38, 95% Confidence Interval 1.04, 1.82). Compared to children with <2% liver fat, those with MAFLD had increased odds of cardio-metabolic-risk-factor clustering (Odds Ratio 7.65, 95% Confidence Interval 5.04, 11.62). In this study, no NAFLD-associated childhood risk factors were associated with increased odds of childhood MAFLD, yet the findings suggest that ethnicity could be, despite mostly explained by socio-economic factors. Use of MAFLD criteria, rather than NAFLD, may identify children at risk for impaired cardio-metabolic health. Erasmus University MC, the Netherlands Organisation for Health Research and Development, the Ministry of Health, Welfare, and Sport, and the European Research Council.
Sections du résumé
Background
UNASSIGNED
Non-Alcoholic Fatty Liver Disease (NAFLD) is defined as increased liver fat percentage, and is the most common chronic liver disease in children. Rather than NAFLD, Metabolic-Associated Fatty Liver Disease (MAFLD), defined as increased liver fat with presence of adverse cardio-metabolic measures, might have more clinical relevance in children. We assessed the prevalence, risk-factors and cardio-metabolic outcomes of MAFLD at school-age.
Methods
UNASSIGNED
This cross-sectional analysis was embedded in an ongoing population-based prospective cohort study started in 2001, in the Netherlands. In 1910 children of 10 years, we measured liver fat fraction by magnetic resonance imaging (MRI), body mass index (BMI), blood pressure, and lipids, insulin, and glucose concentrations. Childhood lifestyle factors were obtained through questionnaires. MAFLD was defined as ≥2% liver fat in addition to excess adiposity (BMI or visceral adiposity), presence of metabolic risk (blood pressure, triglycerides and HDL-concentrations) or prediabetes (glucose).
Findings
UNASSIGNED
Of all children, 49.6% had ≥2% liver fat, and 25.2% fulfilled the criteria of MAFLD. Only non-European descent was associated with increased odds of MAFLD at nominal significance (Odds Ratio 1.38, 95% Confidence Interval 1.04, 1.82). Compared to children with <2% liver fat, those with MAFLD had increased odds of cardio-metabolic-risk-factor clustering (Odds Ratio 7.65, 95% Confidence Interval 5.04, 11.62).
Interpretation
UNASSIGNED
In this study, no NAFLD-associated childhood risk factors were associated with increased odds of childhood MAFLD, yet the findings suggest that ethnicity could be, despite mostly explained by socio-economic factors. Use of MAFLD criteria, rather than NAFLD, may identify children at risk for impaired cardio-metabolic health.
Funding
UNASSIGNED
Erasmus University MC, the Netherlands Organisation for Health Research and Development, the Ministry of Health, Welfare, and Sport, and the European Research Council.
Identifiants
pubmed: 37855025
doi: 10.1016/j.eclinm.2023.102248
pii: S2589-5370(23)00425-X
pmc: PMC10579278
doi:
Types de publication
Journal Article
Langues
eng
Pagination
102248Informations de copyright
© 2023 The Author(s).
Déclaration de conflit d'intérêts
We declare no competing interests.
Références
Obes Rev. 2012 Nov;13(11):985-1000
pubmed: 22731928
Int J Public Health. 2021 Oct 06;66:1604371
pubmed: 34690666
Ann Clin Biochem. 2014 Nov;51(Pt 6):672-9
pubmed: 24448679
Hepatology. 2015 Jun;61(6):1887-95
pubmed: 25529941
Endocrinol Diabetes Metab. 2020 Sep 17;3(4):e00184
pubmed: 33102800
Lancet Gastroenterol Hepatol. 2021 Oct;6(10):864-873
pubmed: 34364544
J Pediatr Gastroenterol Nutr. 2017 Feb;64(2):319-334
pubmed: 28107283
J Magn Reson Imaging. 2011 Oct;34(4):729-749
pubmed: 22025886
Obes Rev. 2017 Sep;18(9):1050-1060
pubmed: 28544608
Liver Int. 2020 Dec;40(12):3018-3030
pubmed: 32997882
Obes Rev. 2011 May;12(5):e504-15
pubmed: 21348916
Hepatology. 2020 Jul;72(1):119-129
pubmed: 31680281
Hepatol Int. 2023 Apr;17(2):350-356
pubmed: 36471232
Blood Press Monit. 2006 Oct;11(5):281-91
pubmed: 16932037
Lancet Gastroenterol Hepatol. 2021 Sep;6(9):743-753
pubmed: 34265276
World J Hepatol. 2021 Jul 27;13(7):763-773
pubmed: 34367497
J Hepatol. 2020 Jul;73(1):202-209
pubmed: 32278004
Int J Pediatr Obes. 2010 Dec;5(6):458-60
pubmed: 20233144
Ann Hepatol. 2023 Jun 24;:101133
pubmed: 37364816
Nutrients. 2022 Oct 28;14(21):
pubmed: 36364818
Clin Gastroenterol Hepatol. 2014 May;12(5):765-73
pubmed: 24090729
Eur J Epidemiol. 2016 Dec;31(12):1243-1264
pubmed: 28070760
Clin Gastroenterol Hepatol. 2021 Oct;19(10):2138-2147.e10
pubmed: 33348045
PLoS One. 2015 Oct 29;10(10):e0140908
pubmed: 26512983
Acta Paediatr Scand. 1991 Aug-Sep;80(8-9):756-62
pubmed: 1957592
J Dig Dis. 2020 Jul;21(7):372-384
pubmed: 32369237
Hepatol Res. 2021 Nov;51(11):1115-1128
pubmed: 34129272